Study: Lenvatinib-Everolimus Combination Can Improve PFS in Renal Cell Carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Lenvatinib, used in combination with everolimus, demonstrated significantly improved progression-free survival compared everolimus alone in people with metastatic renal cell carcinoma following prior VEGF-targeted therapy in a phase II trial.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login